STOK - Stoke Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Bedford,
United States
Type: Equity
STOK price evolution
STOK
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $193.55 | $179.15 | $192.01 | |
| Short term investments | $88.51 | $9.95 | ||
| Net receivables | $0.69 | $0.3 | $0.01 | $0.06 |
| Inventory | ||||
| Total current assets | $253.61 | $296.99 | $193.28 | $215.34 |
| Long term investments | $0.49 | |||
| Property, plant & equipment | $9.26 | $10.27 | $11.34 | $12.43 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $10.76 | $11.91 | $13 | |
| Total investments | $89 | $9.95 | ||
| Total assets | $293.32 | $307.76 | $205.18 | $228.34 |
| Current liabilities | ||||
| Accounts payable | $2.48 | $3.94 | $2.1 | $1.7 |
| Deferred revenue | $43 | $45.96 | $48.38 | |
| Short long term debt | ||||
| Total current liabilities | $49.87 | $44.5 | $35.59 | $30.82 |
| Long term debt | ||||
| Total noncurrent liabilities | $20.55 | $29.25 | $37.96 | |
| Total debt | ||||
| Total liabilities | $61.21 | $65.05 | $64.84 | $68.78 |
| Shareholders' equity | ||||
| Retained earnings | -$480.35 | -$453.92 | -$428.22 | -$401.85 |
| Other shareholder equity | $0.17 | -$0.01 | -$0.02 | |
| Total shareholder equity | $242.71 | $140.34 | $159.56 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $192.01 | $114.13 | $145.46 | $287.51 |
| Short term investments | $9.95 | $116.04 | $74.92 | |
| Net receivables | $0.06 | $0.59 | $0.13 | |
| Inventory | ||||
| Total current assets | $215.34 | $244.07 | $229.22 | $293.93 |
| Long term investments | ||||
| Property, plant & equipment | $12.43 | $11.43 | $9.08 | $3.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $13 | $12 | $9.65 | $4 |
| Total investments | $9.95 | $116.04 | $74.92 | |
| Total assets | $228.34 | $256.07 | $238.87 | $297.93 |
| Current liabilities | ||||
| Accounts payable | $1.7 | $0.77 | $2.38 | $1.5 |
| Deferred revenue | $48.38 | $51.74 | ||
| Short long term debt | ||||
| Total current liabilities | $30.82 | $31.39 | $17.14 | $11.43 |
| Long term debt | ||||
| Total noncurrent liabilities | $37.96 | $39.82 | $3.95 | $0.42 |
| Total debt | ||||
| Total liabilities | $68.78 | $71.22 | $21.09 | $11.85 |
| Shareholders' equity | ||||
| Retained earnings | -$401.85 | -$297.15 | -$196.08 | -$110.28 |
| Other shareholder equity | -$0.02 | -$1.18 | -$0.17 | |
| Total shareholder equity | $159.56 | $184.85 | $217.78 | $286.08 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.89 | $4.83 | $4.22 | $2.8 |
| Cost of revenue | ||||
| Gross Profit | $4.83 | $4.22 | $2.8 | |
| Operating activities | ||||
| Research & development | $21.14 | $22.37 | $21.78 | |
| Selling, general & administrative | $13.04 | $10.22 | $10.61 | |
| Total operating expenses | $34.9 | $34.17 | $32.59 | $32.39 |
| Operating income | -$29.34 | -$28.37 | -$29.59 | |
| Income from continuing operations | ||||
| EBIT | -$29.39 | -$28.8 | -$29.55 | |
| Income tax expense | ||||
| Interest expense | $3.54 | -$3.69 | -$2.43 | -$2.59 |
| Net income | ||||
| Net income | -$26.43 | -$25.7 | -$26.37 | -$26.96 |
| Income (for common shares) | -$25.7 | -$26.37 | -$26.96 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.78 | $12.4 | ||
| Cost of revenue | ||||
| Gross Profit | $8.78 | $12.4 | ||
| Operating activities | ||||
| Research & development | $82.23 | $77.84 | $54.17 | $32.2 |
| Selling, general & administrative | $41.32 | $38.92 | $31.9 | $20.85 |
| Total operating expenses | $123.55 | $116.76 | $86.06 | $53.04 |
| Operating income | -$114.77 | -$104.36 | -$86.06 | -$53.04 |
| Income from continuing operations | ||||
| EBIT | -$114.61 | -$104.19 | -$85.69 | -$52.24 |
| Income tax expense | ||||
| Interest expense | -$9.91 | -$3.12 | $0.12 | |
| Net income | ||||
| Net income | -$104.7 | -$101.07 | -$85.81 | -$52.24 |
| Income (for common shares) | -$104.7 | -$101.07 | -$85.81 | -$52.24 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$25.7 | -$26.37 | -$26.96 | |
| Operating activities | ||||
| Depreciation | $1.11 | $1.11 | $1.22 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.43 | $5.41 | $6.06 | |
| Total cash flows from operations | -$17.48 | -$24.57 | -$20.65 | |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$0.01 | -$0.23 | |
| Investments | -$88.23 | $10 | $15 | |
| Total cash flows from investing | -$108.29 | -$88.28 | $9.99 | $14.77 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $120.65 | $1.72 | $7.34 | |
| Net borrowings | ||||
| Total cash flows from financing | $130.53 | $120.65 | $1.72 | $7.34 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$41.43 | $14.89 | -$12.86 | $1.47 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$104.7 | -$101.07 | -$85.81 | -$52.24 |
| Operating activities | ||||
| Depreciation | $4.73 | $3.54 | $2.23 | $1.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.26 | $22.85 | $16.45 | $5.77 |
| Total cash flows from operations | -$81.07 | -$31.87 | -$66.91 | -$42.22 |
| Investing activities | ||||
| Capital expenditures | -$1.62 | -$3.96 | -$1.2 | -$1.05 |
| Investments | $107.56 | -$41.92 | -$75.23 | |
| Total cash flows from investing | $105.95 | -$45.88 | -$76.43 | -$1.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $53.01 | $46.41 | $1.29 | $108.59 |
| Net borrowings | ||||
| Total cash flows from financing | $53.01 | $46.41 | $1.28 | $108.11 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $77.89 | -$31.34 | -$142.05 | $64.84 |
News
Fundamentals
| Market cap | $476.47M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 52.94M |
| Revenue | $16.74M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$105.46M |
| Revenue Q/Q | 47.94% |
| Revenue Y/Y | 81.06% |
| P/E ratio | -4.52 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 28.46 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.99 |
|---|---|
| ROA | -40.77% |
| ROE | N/A |
| Debt/Equity | 0.43 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 5.09 |
| Quick ratio | N/A |